Chemistry:NH130

From HandWiki

NH130 is a highly selective serotonin 5-HT2A receptor inverse agonist which is under development for the treatment of Parkinson's disease psychosis.[1][2][3][4] It is taken orally.[2][4] The drug's time to peak levels is 3.0 to 4.5 hours and its elimination half-life is 13.7 to 18.2 hours.[4] NH130 is under development by Jiangsu Nhwa Pharmaceutical in China.[1][2][4] As of November 2025, it is in phase 2 clinical trials.[1]

See also

  • Serotonin 5-HT2A receptor antagonist
  • List of investigational Parkinson's disease drugs

References

  1. 1.0 1.1 1.2 "Delving into the Latest Updates on NH-130 with Synapse". 21 November 2025. https://synapse.patsnap.com/drug/e4911afcffc64f1e8097fc5d2aaf277c. 
  2. 2.0 2.1 2.2 "NH-130 Drug Profile". https://pryzm.ozmosi.com/product/30903. 
  3. "Serotonin 2A (5-HT2A) receptor as evolving biological target: function, structure, ligands and role in the therapy of neuropsychiatric diseases". Neuropharmacology 279. November 2025. doi:10.1016/j.neuropharm.2025.110622. PMID 40752586. https://ruj.uj.edu.pl/handle/item/561126. 
  4. 4.0 4.1 4.2 4.3 "Phase I clinical trial of NH130 and the prediction of its pharmacokinetics using physiologically based pharmacokinetic modeling". Frontiers in Pharmacology 15. 2024. doi:10.3389/fphar.2024.1474868. PMID 39329116. "Following the success of pimavanserin, the search for new molecules with enhanced efficacy and an improved safety profile for treating PDP began. In Phase 1 clinical trial (CTR20230409), healthy volunteers received the compound NH130, a highly selective inverse agonist of the 5-HT2AR designed to mimic pimavanserin. The results confirmed NH130’s favourable safety and tolerability. Based on these findings, further optimization of the compound and Phase 2 studies in patients with PDP are planned (K. Zhang et al., 2024).".